Cited by 6,670Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Osteoclast differentiation and activation

Boyle, William J., Simonet, W. Scott, Lacey, David L.·2003·Nature

Open this paper in CoChat — free account

Abstract

Osteoclasts are specialized cells derived from the monocyte/macrophage haematopoietic lineage that develop and adhere to bone matrix, then secrete acid and lytic enzymes that degrade it in a specialized, extracellular compartment. Discovery of the RANK signalling pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass. Further study of this pathway is providing the molecular basis for developing therapeutics to treat osteoporosis and other diseases of bone loss.

Integrity signals

Registry

Crossref · 10.1038/nature01658

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citation
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citation
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citation
Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citation
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z. (2002) · Nature reviews. Cancer · doi:10.1038/nrc780 · Cited by 2,476
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Self-citation
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citation
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signalingPreprint
Lomaga, M. A., Yeh, W., Sarosi, I., Duncan, G. S., Furlonger, C. L., Ho, A. P., Morony, S., Capparelli, C., Van, G. Y., Kaufman, S., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.1015 · Cited by 1,265
Self-citation
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,264
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,185
Self-citation
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
Self-citation
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells
Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Requirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
Self-citation
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 825
Self-citation
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746
Osteoclast-Like Cell Formation and its Regulation by Osteotropic Hormones in Mouse Bone Marrow Cultures*
Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., BOYDE, A., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-122-4-1373 · Cited by 731
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H. I., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 719
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors.
Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, D. M., & Suda, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1741 · Cited by 693
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Self-citation
Distinct molecular mechanism for initiating TRAF6 signalling
Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K., Segal, D., Dzivenu, O. K., Vologodskaia, M., Yim, M., et al. (2002) · Nature · doi:10.1038/nature00888 · Cited by 671
TRANCE, a TNF Family Member, Activates Akt/PKB through a Signaling Complex Involving TRAF6 and c-Src
Wong, B. R., Besser, D., Kim, N., Arron, J. R., Vologodskaia, M., Hanafusa, H., & Choi, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80232-4 · Cited by 594
Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)
Matsumoto, M., SUDO, T., Saito, T., Osada, H., & Tsujimoto, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001229200 · Cited by 513
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., Macpherson, H. K., Wallace, R. G. H., Hul, W. V., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 484
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis
Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T. S., Tanaka, S., & Inoue, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1271 · Cited by 473
Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification
Li, Y., Chen, W., Liang, Y., Li, E., & Stashenko, P. (1999) · Nature Genetics · doi:10.1038/70563 · Cited by 467
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 446
Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428
Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)
Darnay, B. G., Haridas, V., Ni, J., Moore, P. A., & Aggarwal, B. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20551 · Cited by 414
Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function
Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.9.7634 · Cited by 411
RANK Ligand and Osteoprotegerin
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 408
Osteoclast Differentiation Factor Acts as a Multifunctional Regulator in Murine Osteoclast Differentiation and Function
Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., & Suda, T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.434 · Cited by 404
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391
Self-citation
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator
Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T., & Takeya, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205063200 · Cited by 377
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms
David, J., Sabapathy, K., Hoffmann, O., Idarraga, M. H., & Wagner, E. F. (2002) · Journal of Cell Science · doi:10.1242/jcs.00082 · Cited by 334
The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily
Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D. J., & Dougall, W. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.34120 · Cited by 330
TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL.
Fuller, K., Murphy, C., Kirstein, B., Fox, S., & Chambers, T. (2002) · Endocrinology · doi:10.1210/endo.143.3.8701 · Cited by 322
U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells
Hotokezaka, H., Sakai, E., Kanaoka, K., Saito, K., Matsuo, K.-I., Kitaura, H., Yoshida, N., & Nakayama, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208284200 · Cited by 316
p38 MAPK-Mediated Signals Are Required for Inducing Osteoclast Differentiation But Not for Osteoclast Function
Li, X., Udagawa, N., Itoh, K., Suda, K., Murase, Y., Nishihara, T., Suda, T., & Takahashi, N. (2002) · Endocrinology · doi:10.1210/endo.143.8.8954 · Cited by 288
Receptor Activator of NF-κB Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase Kinase Kinase through a Signaling Complex Containing RANK, TAB2, and TRAF6
Mizukami, J., Takaesu, G., Akatsuka, H., Sakurai, H., Ninomiya‐Tsuji, J., Matsumoto, K., & Sakurai, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.4.992-1000.2002 · Cited by 282
A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function
Armstrong, A. P., Tometsko, M. E., Glaccum, M. B., Sutherland, C. L., Cosman, D. J., & Dougall, W. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202009200 · Cited by 252
SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts
Takeshita, S., Namba, N., Zhao, J. J., Jiang, Y., Genant, H. K., Silva, M. J., Brodt, M. D., Helgason, C. D., Kalesnikoff, J., Rauh, M. J., et al. (2002) · Nature Medicine · doi:10.1038/nm752 · Cited by 250
Microphthalmia Transcription Factor Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-κB Ligand Signaling
Mansky, K. C., Sankar, U., Han, J., & Ostrowski, M. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111696200 · Cited by 248
Genetic control of skeletal development
Wagner, E. F., & Karsenty, G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00228-8 · Cited by 229
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
Cundy, T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2119 · Cited by 228
Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling
Wei, S., Wang, M. W.-H., Teitelbaum, S. L., & Ross, F. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104957200 · Cited by 202
Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures
Langdahl, B. L., Carstens, M., Stenkjær, L. L., & Eriksen, E. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1245 · Cited by 190
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187
Self-citation
Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB
Cappellen, D., Luong-Nguyen, N.-H., Bongiovanni, S., Grenet, O., Wanke, C., & Šuša, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200434200 · Cited by 184
Expansile Skeletal Hyperphosphatasia Is Caused by a 15-Base Pair Tandem Duplication inTNFRSF11AEncoding RANK and Is Allelic to Familial Expansile Osteolysis
Whyte, M. P., & Hughes, A. E. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.26 · Cited by 178
NF-κB p50 and p52 Expression Is Not Required for RANK-Expressing Osteoclast Progenitor Formation but Is Essential for RANK- and Cytokine-Mediated Osteoclastogenesis
Xing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165
Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis
Mizuno, A., Kanno, T., HOSHI, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A., et al. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200049 · Cited by 148
Bone homeostasis
Rodan, G. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13361 · Cited by 148
The osteopetrotic mutation toothless ( tl ) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification
Wesenbeeck, L. V., Odgren, P. R., MacKay, C. A., D’Angelo, M., Safadi, F. F., Popoff, S. N., Hul, W. V., & Marks, S. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202332999 · Cited by 122
Osteoclast biology: Lessons from mammalian mutations
Marks, S. C. (1989) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320340110 · Cited by 110
Regulation of osteoclastogenesis and RANK expression by TGF‐β1
Yan, T., Riggs, B. L., Boyle, W. J., & Khosla, S. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1200 · Cited by 109
Self-citation
Regulation of Receptor Activator of NF-κB Ligand-induced Osteoclastogenesis by Endogenous Interferon-β (INF-β) and Suppressors of Cytokine Signaling (SOCS)
Hayashi, T., Kaneda, T., Toyama, Y., Kumegawa, M., & Hakeda, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203836200 · Cited by 97
c- myc Is Required for Osteoclast Differentiation
Battaglino, R. A., Kim, D., Fu, J. Q., Vaage, B., Fu, X.-Y., & Stashenko, P. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.5.763 · Cited by 97
Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO
Chagraoui, H., Tulliez, M., Smayra, T., Komura, E., Giraudier, S., Yun, T. J., Lassau, N., Vainchenker, W., & Wendling, F. (2003) · Blood · doi:10.1182/blood-2002-09-2839 · Cited by 97
Possible Involvement of IκB Kinase 2 and MKK7 in Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor κB Ligand
Yamamoto, A., Miyazaki, T., Kadono, Y., Takayanagi, H., Miura, T., Nishina, H., Katada, T., Wakabayashi, K., Oda, H., Nakamura, K., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.4.612 · Cited by 85
TAK1-dependent Activation of AP-1 and c-Jun N-terminal Kinase by Receptor Activator of NF-κB
Lee, S. W., Han, S.-I., Kim, H., & Lee, Z. H. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.4.371 · Cited by 77
The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
The Immunosuppressant Rapamycin, Alone or with Transforming Growth Factor-b, Enhances Osteoclast Differentiation of RAW264.7 Monocyte-Macrophage Cells in the Presence of RANK-Ligand
Shui, C., Riggs, B. L., & Khosla, S. (2002) · Calcified Tissue International · doi:10.1007/s00223-001-1138-3 · Cited by 62
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression
Kim, Y. H., Kim, G.-S., & Baek, J. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.21 · Cited by 58
Mouse models of abnormal skeletal development and homeostasis
McLean, W., & Olsen, B. R. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02458-1 · Cited by 58
A block at the toll gate
Mak, T. W., & Yeh, W. (2002) · Nature · doi:10.1038/418835a · Cited by 17

Sorted by citations

The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
“Osteoclasts are macrophage-like cells that play an important role in bone turnover (100).”
Background
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,333
“Osteoclasts, derived from the monocytic branch of hematopoiesis, can be differentiated and stimulated through the expression of cytokines, including M-CSF, RANKL, IL-6, IL-8, and IL-11 (Boyle et al., 2003).”
Background
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Normal Bone Anatomy and Physiology
Clarke, B. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04151206 · Cited by 2,192
“H ions acidify the resorption compartment beneath osteoclasts to dissolve the mineral component of bone matrix, whereas cathepsin K digests the proteinaceous matrix, which is mostly composed of type I collagen (11).”
Background
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067
“Excessive bone loss mediated by osteoclasts plays a major role in certain pathologic conditions, such as rheumatoid arthritis (RA) and osteoporosis (67, 68).”
Background

See all 6,670

Authors: Boyle, W. J., Simonet, W. S., & Lacey, D. L.
Affiliations: Amgen (United States) (US)
Corresponding author: Boyle, William J.
ORCID: Boyle, William J.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2003-05
Volume: 423
Issue: 6937
Pages: 337-342
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature01658
OpenAlex: W2093252878
Cited by: 6,670
References: 77
Citations by year: 2026: 240 · 2025: 269 · 2024: 294 · 2023: 357 · 2022: 349 · 2021: 404 · 2020: 376 · 2019: 381 · 2018: 371 · 2017: 324 · 2016: 311 · 2015: 332 · 2014: 352 · 2013: 315 · 2012: 336
FWCI: 11.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: osteoclasts, osteoclastogenesis, bone resorption, monocyte/macrophage lineage, bone matrix degradation, hormonal regulation of bone, osteoporosis
MeSH terms: Animals, Bone Resorption, Carrier Proteins, Cell Differentiation, Glycoproteins, Humans, Membrane Glycoproteins, Osteoclasts, Osteoporosis, Signal Transduction, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoclast differentiation and activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks